Table 1. Study Calendar

Day	Screen	Treatment Day 1 (TD1)			Follow-Up Period 1					Treatment Day 2 (TD2)			Follow-Up Period 2										EDC Timepoints
	(-)7 to 1	Pre-dose	Dose	Post-Dose	11	29	42	59	84	Pre-dose	Dose	Post-Dose	TD2 +3	TD2 +11	TD2 + 29	TD2 +42	TD2 +59	TD2 +84	TD2 +112	TD2 +140	TD2+168 / EOT	TD2 + 252/EOS	
Week		1			2	4	6	8	12	12			TD2 + 0	TD2 +2	TD2 +4	TD2 +6	TD2 +8	TD2 +12	TD2 +16	TD2 +20	TD+24	TD2 +36	
Visit Number		1			2	3	4	5	6	7			8	9	10	11	12	13	14	15	16	17	
Window (Days)		±3			±3	±3	±3	±3	±3	-4 (weeks)/ +2 (weeks)			-1/+2	±3	±3	±3	±3	±3	±3	±3	±3	±7	
Screening Only																							
Inclusion/Exclusion Criteria	X																						Screening
SARS-CoV-2 Spike Antibody	X																						Screening
Informed Consent	X																						Screening
Day 1 Only																							
Demographics		X																					Baseline
Medical History		X																					Baseline
Height and Weight		X																					Baseline
SARS-CoV-2 Vaccination History		X																					Baseline
Verification of Inclusion/Exclusion Criteria		X																					Baseline
Treatment																							
Study Drug Administration			X								X												TD1, TD2
Safety and Tolerability Assessments																							
Vital Signs		X		X*	X	X				X		X*	X	X	X						X		TD1 (pre- and post-dose), V2, V3, TD2 (pre- and post-dose), V8, V9, V10, V16
Physical Exam		X								X											X		TD1, TD2, V16
Targeted Exam					X	X							X	X	X								V2, V3, V8, V9, V10
Karnofsky Performance Status		X								X											X		TD1, TD2, V16
12-Lead ECG		X								X											X		TD1, TD2, V16
Pregnancy Test		X								X													TD1, TD2

Day	Screen	Treatment Day 1 (TD1)			Follow-Up Period 1					Treatment Day 2 (TD2)			Follow-Up Period 2									EDC Timepoints
	(-)7 to 1	Pre-dose	Dose	Post-Dose	11	29	42	59	84	Pre-dose	Dose	Post-Dose	TD2 +3	TD2 +11	TD2 + 29	TD2 +42	TD2 +59	TD2 +84	TD2 +112	TD2 +140	TD2+168 / EOT	TD2 + 252/EOS	
Week		1			2	4	6	8	12	12			TD2 + 0	TD2 +2	TD2 +4	TD2 +6	TD2 +8	TD2 +12	TD2 +16	TD2 +20	TD+24	TD2 +36	
Visit Number		1			2	3	4	5	6	7			8	9	10	11	12	13	14	15	16	17	
Window (Days)		±3			± 3	± 3	± 3	±3	±3	-4 (weeks)/ +2 (weeks)			-1/+2	±3	±3	±3	±3	±3	±3	±3	±3	±7	
Local Laboratory testing		X				X				X			X		X						X		TD1, V3, TD2, V8, V10, V16
Targeted Concomitant Medications	←																					→	All visits
TEAE/AESI Monitoring	←																					→	All visits
SAE Monitoring	←																					→	All visits
Serum ADA		X				X				X					X						X		TD1, V3, TD2, V10, V16
Phone Call Follow-up Visit (Not applicable on Day 59 and Day TD2+59 if participant is getting Serum for PK assessment)							X	X	X							X	X	X	X	X		X	V4, V5, V6, V11, V12, V13, V14, V15, V17
Serum for PK Assessment (Day 59 and TD2+59 assessments are only applicable for Lead-In PK and Lead-In safety second dose cohorts, respectively)				X	X	X		X		X		X		X	X		X				X		TD1, V2, V3, V5, TD2, V9, V10, V12, V16
Biweekly Anterior Nasal Swab SARS-CoV-2 RT-PCR	←																					→	All visits
COVID-19 Symptom Assessment	←																					→	All visits
SF-36 Quality of Life Assessment		X								X											X		TD1, TD2, V16

Day	Screen	Treatment Day 1 (TD1)			Follow-Up Period 1					Treatment Day 2 (TD2)			Follow-Up Period 2									EDC Timepoints
	(-)7 to 1	Pre-dose	Dose	Post-Dose	11	29	42	59	84	Pre-dose	Dose	Post-Dose	TD2 +3	TD2 +11	TD2 + 29	TD2 +42	TD2 +59	TD2 +84	TD2 +112	TD2 +140	TD2+168 / EOT	TD2 + 252/EOS	
Week		1			2	4	6	8	12	12			TD2 + 0	TD2 +2	TD2 +4	TD2 +6	TD2 +8	TD2 +12	TD2 +16	TD2 +20	TD+24	TD2 +36	
Visit Number		1			2	3	4	5	6	7			8	9	10	11	12	13	14	15	16	17	
Window (Days)		±3			± 3	± 3	± 3	±3	±3	-4 (weeks)/ +2 (weeks)			-1/+2	±3	±3	±3	±3	±3	±3	±3	±3	±7	
NIAID-OS Ordinal Scale	←	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	→	Only if subjects develop COVID-19
Transplant-Associated Endpoints	←	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	→	All visits

*Vital signs should be assessed within 30 minutes after the end of the infusion.